Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 43
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Hopf, Stefan Garner-Spitzer, Erika Hofer, Michael Kundi, Michael and Wiedermann, Ursula 2016. Comparable immune responsiveness but increased reactogenicity after subcutaneous versus intramuscular administration of tick borne encephalitis (TBE) vaccine. Vaccine, Vol. 34, Issue. 17, p. 2027.

    Hermann, Laura L. Gupta, Swati B. Manoff, Susan B. Kalayanarooj, Siripen Gibbons, Robert V. and Coller, Beth-Ann G. 2015. Advances in the understanding, management, and prevention of dengue. Journal of Clinical Virology, Vol. 64, p. 153.

    Pitcher, T. J. Sarathy, V. V. Matsui, K. Gromowski, G. D. Huang, C. Y.- H. and Barrett, A. D. T. 2015. Functional analysis of dengue virus (DENV) type 2 envelope protein domain 3 type-specific and DENV complex-reactive critical epitope residues. Journal of General Virology, Vol. 96, Issue. Pt_2, p. 288.

    Stock, N.K. Escadafal, C. Achazi, K. Cissé, M. and Niedrig, M. 2015. Development and characterization of polyclonal peptide antibodies for the detection of Yellow fever virus proteins. Journal of Virological Methods, Vol. 222, p. 110.

    Streatfield, Stephen J. Kushnir, Natasha and Yusibov, Vidadi 2015. Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents. Plant Biotechnology Journal, Vol. 13, Issue. 8, p. 1136.

    Tang, William W Grewal, Rajvir and Shresta, Sujan 2015. Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models. Current Opinion in Virology, Vol. 13, p. 61.

    Rothman, A. L. 2014. DHIM Supporting Immunologic Investigations and the Identification of Immune Correlates of Protection. Journal of Infectious Diseases, Vol. 209, Issue. suppl 2, p. S61.

    Wang, Hsi-Kai Tsai, Cheng-Han Chen, Kuan-Hung Tang, Chung-Tao Leou, Jiun-Shyang Li, Pi-Chun Tang, Yin-Liang Hsieh, Hsyue-Jen Wu, Han-Chung and Cheng, Chao-Min 2014. Cellulose-Based Diagnostic Devices for Diagnosing Serotype-2 Dengue Fever in Human Serum. Advanced Healthcare Materials, Vol. 3, Issue. 2, p. 187.

    Yamanaka, Atsushi Suzuki, Ryosuke and Konishi, Eiji 2014. Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays. Vaccine, Vol. 32, Issue. 34, p. 4289.

    Beck, Cécile Jimenez-Clavero, Miguel Leblond, Agnès Durand, Benoît Nowotny, Norbert Leparc-Goffart, Isabelle Zientara, Stéphan Jourdain, Elsa and Lecollinet, Sylvie 2013. Flaviviruses in Europe: Complex Circulation Patterns and Their Consequences for the Diagnosis and Control of West Nile Disease. International Journal of Environmental Research and Public Health, Vol. 10, Issue. 11, p. 6049.

    Chan, Kuan Rong Ong, Eugenia Z and Ooi, Eng Eong 2013. Therapeutic antibodies as a treatment option for dengue fever. Expert Review of Anti-infective Therapy, Vol. 11, Issue. 11, p. 1147.

    Guzman, Maria G. Alvarez, Mayling and Halstead, Scott B. 2013. Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Archives of Virology, Vol. 158, Issue. 7, p. 1445.

    Julander, Justin G. 2013. Experimental therapies for yellow fever. Antiviral Research, Vol. 97, Issue. 2, p. 169.

    Li, X.-Q. Qiu, L.-W. Chen, Y. Wen, K. Cai, J.-P. Chen, J. Pan, Y.-X. Li, J. Hu, D.-M. Huang, Y.-F. Liu, L.-D. Ding, X.-X. Guo, Y.-h. and Che, X.-Y. 2013. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design. Journal of General Virology, Vol. 94, Issue. Pt_10, p. 2191.

    Monath, Thomas P. Gershman, Mark Erin Staples, J. and Barrett, Alan D.T. 2013. Vaccines.

    Sambri, V. Capobianchi, M. Charrel, R. Fyodorova, M. Gaibani, P. Gould, E. Niedrig, M. Papa, A. Pierro, A. Rossini, G. Varani, S. Vocale, C. and Landini, M.P. 2013. West Nile virus in Europe: emergence, epidemiology, diagnosis, treatment, and prevention. Clinical Microbiology and Infection, Vol. 19, Issue. 8, p. 699.

    Sambri, Vittorio Capobianchi, Maria Cavrini, Francesca Charrel, Rémi Donoso-Mantke, Olivier Escadafal, Camille Franco, Leticia Gaibani, Paolo Gould, Ernest Niedrig, Matthias Papa, Anna Pierro, Anna Rossini, Giada Sanchini, Andrea Tenorio, Antonio Varani, Stefania Vázquez, Ana Vocale, Caterina and Zeller, Herve 2013. Diagnosis of West Nile Virus Human Infections: Overview and Proposal of Diagnostic Protocols Considering the Results of External Quality Assessment Studies. Viruses, Vol. 5, Issue. 10, p. 2329.

    Sjatha, Fithriyah Takizawa, Yamato Kotaki, Tomohiro Yamanaka, Atsushi and Konishi, Eiji 2013. Comparison of infection-neutralizing and -enhancing antibody balance induced by two distinct genotype strains of dengue virus type 1 or 3 DNA vaccines in mice. Microbes and Infection, Vol. 15, Issue. 12, p. 828.

    Spiroski, Mirko Milenkovic, Zvonko Petlichkovski, Aleksandar Ivanovski, Ljubomir Topuzovska, Irena Kondova and Djulejic, Eli 2013. Killer cell immunoglobulin-like receptor genes in four human West Nile virus infections reported 2011 in the Republic of Macedonia. Human Immunology, Vol. 74, Issue. 3, p. 389.

    Zhou, Yang Austin, S.Kyle Fremont, Daved H. Yount, Boyd L. Huynh, Jeremy P. de Silva, Aravinda M. Baric, Ralph S. and Messer, William B. 2013. The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1. Virology, Vol. 439, Issue. 1, p. 57.

  • Expert Reviews in Molecular Medicine, Volume 10
  • 2008, e12

Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection

  • Theodore C. Pierson (a1) and Michael S. Diamond (a2)
  • DOI:
  • Published online: 01 May 2008

Flaviviruses are a group of positive-stranded RNA viruses that cause a spectrum of severe illnesses globally in more than 50 million individuals each year. While effective vaccines exist for three members of this group (yellow fever, Japanese encephalitis, and tick-borne encephalitis viruses), safe and effective vaccines for several other flaviviruses of clinical importance, including West Nile and dengue viruses, remain in development. An effective humoral immune response is critical for protection against flaviviruses and an essential goal of vaccine development. The effectiveness of virus-specific antibodies in vivo reflects their capacity to inhibit virus entry and spread through several mechanisms, including the direct neutralisation of virus infection. Recent advances in our understanding of the structural biology of flaviviruses, coupled with the use of small-animal models of flavivirus infection, have promoted significant advances in our appreciation of the factors that govern antibody recognition and inhibition of flaviviruses in vitro and in vivo. In this review, we discuss the properties that define the potency of neutralising antibodies and the molecular mechanisms by which they inhibit virus infection. How recent advances in this area have the potential to improve the development of safe and effective vaccines and immunotherapeutics is also addressed.

Corresponding author
*Corresponding author: Theodore C. Pierson, Laboratory of Viral Diseases, NIAID, NIH, 33 North Drive, Room 1E19A.2, Bethesda, MD 20814, USA. Tel: +1 301 451 7977; Fax: 1 301 451 7978; E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

2Y. Zhang (2004) Conformational changes of the flavivirus E glycoprotein. Structure 12, 1607-1618

3F.A. Rey (1995) The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375, 291-298

4Y. Modis (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100, 6986-6991

5Y. Modis (2005) Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79, 1223-1231

6J.J. Chu (2005) Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoprotein. J Gen Virol 86, 405-412

7S.L. Allison (2001) Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 75, 4268-4275

8Y. Modis (2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427, 313-319

9S. Bressanelli (2004) Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J 23, 728-738

10W. Zhang (2003) Visualization of membrane protein domains by cryo-electron microscopy of dengue virus. Nat Struct Biol 10, 907-912

13J.M. Mackenzie and E.G. Westaway (2001) Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 75, 10787-10799

14Y. Zhang (2007) Structure of immature West Nile virus. J Virol 81, 6141-6145

15Y. Zhang (2003) Structures of immature flavivirus particles. EMBO J 22, 2604-2613

16F.X. Heinz (1994) Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM. Virology 198, 109-117

17F. Guirakhoo (1991) Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. J Gen Virol 72, 1323-1329

18S. Mukhopadhyay , R.J. Kuhn and M.G. Rossmann (2005) A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3, 13-22

20S. Mukhopadhyay (2003) Structure of West Nile virus. Science 302, 248

21R.J. Kuhn (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108, 717-725

22T. Kimura , S.W. Gollins and J.S. Porterfield (1986) The effect of pH on the early interaction of West Nile virus with P388D1 cells. J Gen Virol 67, 2423-2433

23S.W. Gollins and J.S. Porterfield (1986) pH-dependent fusion between the flavivirus West Nile and liposomal model membranes. J Gen Virol 67, 157-166

24H. Holzmann (1995) Tick-borne encephalitis virus envelope protein E-specific monoclonal antibodies for the study of low pH-induced conformational changes and immature virions. Arch Virol 140, 213-221

26K. Stiasny (2001) Role of metastability and acidic pH in membrane fusion by tick-borne encephalitis virus. J Virol 75, 7392-7398

28D.M. Eckert and P.S. Kim (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70, 777-810

29P.M. Colman and M.C. Lawrence (2003) The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 4, 309-319

30M. Liao and M. Kielian (2005) Domain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusion. J Cell Biol 171, 111-120

31F. Bai (2007) Antiviral peptides targeting the west nile virus envelope protein. J Virol 81, 2047-2055

32Y.M. Hrobowski , R.F. Garry and S.F. Michael (2005) Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J 2, 49

33J.D. Reeves and A.J. Piefer (2005) Emerging drug targets for antiretroviral therapy. Drugs 65, 1747-1766

34M.S. Diamond (2003) B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77, 2578-2586

35M.S. Diamond (2003) Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol 16, 259-278

36T. Oliphant (2005) Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11, 522-530

37R.B. Tesh (2002) Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg Infect Dis 8, 245-251

38T. Wang (2001) Immunization of mice against West Nile virus with recombinant envelope protein. J Immunol 167, 5273-5277

39D. Ben-Nathan (2003) Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating west nile virus infection in mice. J Infect Dis 188, 5-12

40D.L. Camenga , N. Nathanson and G.A. Cole (1974) Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J Infect Dis 130, 634-641

41J.T. Roehrig (2001) Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann N Y Acad Sci 951, 286-297

43T.R. Kreil (1997) Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin Exp Immunol 110, 358-361

45D.W. Beasley (2004) Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine. Vaccine 22, 3722-3726

46S. Vazquez (2002) Immune response to synthetic peptides of dengue prM protein. Vaccine 20, 1823-1830

47S. Pincus (1992) Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 187, 290-297

48A.K. Falconar (1999) Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol 144, 2313-2330

49G. Colombage (1998) DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250, 151-163

50K.M. Chung (2007) Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells. J Virol 81, 9551-9555

51K.M. Chung (2006) Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol 80, 1340-1351

52P.Y. Shu (2000) Dengue NS1-specific antibody responses: isotype distribution and serotyping in patients with Dengue fever and Dengue hemorrhagic fever. J Med Virol 62, 224-232

54C.A. Gibson , J.J. Schlesinger and A.D. Barrett (1988) Prospects for a virus non-structural protein as a subunit vaccine. Vaccine 6, 7-9

55D.W. Beasley and A.D. Barrett (2002) Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 76, 13097-13100

56T. Oliphant (2006) Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80, 12149-12159

57W.D. Crill and G.J. Chang (2004) Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78, 13975-13986

58J.T. Roehrig , R.A. Bolin and R.G. Kelly (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246, 317-328

59J.T. Roehrig , J.H. Mathews and D.W. Trent (1983) Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. Virology 128, 118-126

60F.X. Heinz (1983) A topological and functional model of epitopes on the structural glycoprotein of tick-borne encephalitis virus defined by monoclonal antibodies. Virology 126, 525-537

62S. Sukupolvi-Petty (2007) Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81, 12816-12826

63M. Throsby (2006) Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 80, 6982-6992

64T. Oliphant (2007) Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81, 11828-11839

65M.D. Sanchez (2007) The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 359, 336-348

68T.C. Pierson (2007) Stoichiometric requirements for antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1, 135-146

70G.D. Gromowski and A.D. Barrett (2007) Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366, 349-360

71K. Stiasny (2006) Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80, 9557-9568

72J.D. Morrey (2006) Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis 194, 1300-1308

73J.D. Morrey (2007) Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother 51, 2396-2402

74G.E. Nybakken (2005) Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437, 764-769

75B. Kaufmann (2006) West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A 103, 12400-12404

76M.N. Krishnan (2007) Rab 5 is required for the cellular entry of dengue and West Nile viruses. J Virol 81, 4881-4885

77H.M. van der Schaar (2007) Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol 81, 12019-12028

78S.W. Gollins and J.S. Porterfield (1985) Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry. J Gen Virol 66, 1969-1982

79J.J. Chu and M.L. Ng (2004) Infectious entry of West Nile virus occurs through a clathrin-mediated endocytic pathway. J Virol 78, 10543-10555

80R. Anderson (2003) Manipulation of cell surface macromolecules by flaviviruses. Adv Virus Res 59, 229-274

81K. Stiasny , C. Koessl and F.X. Heinz (2003) Involvement of lipids in different steps of the flavivirus fusion mechanism. J Virol 77, 7856-7862

82K. Stiasny (2002) Membrane interactions of the tick-borne encephalitis virus fusion protein E at low pH. J Virol 76, 3784-3790

83R. Pantophlet and D.R. Burton (2006) GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 24, 739-769

84R.T. He (1995) Antibodies that block virus attachment to Vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J Med Virol 45, 451-461

85A.D. Jennings (1994) Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect Dis 169, 512-518

86C.W. Mandl (2000) Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J Virol 74, 9601-9609

88W.R. Jiang (1993) Single amino acid codon changes detected in louping ill virus antibody-resistant mutants with reduced neurovirulence. J Gen Virol 74, 931-935

89B. Tassaneetrithep (2003) DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197, 823-829

90E. Navarro-Sanchez (2003) Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 4, 723-728

91A. Sakuntabhai (2005) A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 37, 507-513

92P.Y. Lozach (2005) Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem 280, 23698-23708

93C.W. Davis (2006) The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin). J Biol Chem 281, 37183-37194

94C.W. Davis (2006) West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol 80, 1290-1301

95E. Pokidysheva (2006) Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124, 485-493

96D.A. Mitchell , A.J. Fadden and K. Drickamer (2001) A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 276, 28939-28945

97S.W. Gollins and J.S. Porterfield (1986) A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 321, 244-246

98G.E. Nybakken (2006) Crystal structure of the west nile virus envelope glycoprotein. J Virol 80, 11467-11474

99K. Stiasny (2007) Probing the flavivirus membrane fusion mechanism by using monoclonal antibodies. J Virol 81, 11526-11531

100E. Mehlhop (2005) Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol 79, 7466-7477

101E. Mehlhop and M.S. Diamond (2006) Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med 203, 1371-1381

102K. Meyer (2002) Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol 76, 2150-2158

103J.Q. Feng , K. Mozdzanowska and W. Gerhard (2002) Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 76, 1369-1378

104J.J. Schlesinger and S. Chapman (1995) Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J Gen Virol 76, 217-220

105J.J. Schlesinger , M. Foltzer and S. Chapman (1993) The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology 192, 132-141

106S.B. Halstead (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60, 421-467

107A.L. Rothman (2003) Immunology and immunopathogenesis of dengue disease. Adv Virus Res 60, 397-419

108D.W. Vaughn (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181, 2-9

111W.B. Klimstra (2005) Targeting Sindbis virus-based vectors to Fc receptor-positive cell types. Virology 338, 9-21

112I.D. Iankov (2006) Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol 80, 8530-8540

113K.J. Huang (2006) The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol 176, 2825-2832

114M.J. Wallace (2003) Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol 84, 1723-1728

115A. Takada (2003) Antibody-dependent enhancement of Ebola virus infection. J Virol 77, 7539-7544

116J. Girn , M. Kavoosi and J. Chantler (2002) Enhancement of coxsackievirus B3 infection by antibody to a different coxsackievirus strain. J Gen Virol 83, 351-358

118A. Takeda , C.U. Tuazon and F.A. Ennis (1988) Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242, 580-583

119M. Tamura , R.G. Webster and F.A. Ennis (1991) Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry. Virology 182, 211-219

120D.M. Morens and S.B. Halstead (1990) Measurement of antibody-dependent infection enhancement of four dengue virus serotypes by monoclonal and polyclonal antibodies. J Gen Virol 71, 2909-2914

121D.M. Morens , S.B. Halstead and N.J. Marchette (1987) Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microb Pathog 3, 231-237

123H.B. Gimenez , H.M. Keir and P. Cash (1989) In vitro enhancement of respiratory syncytial virus infection of U937 cells by human sera. J Gen Virol 70, 89-96

126E.A. Gould and A. Buckley (1989) Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J Gen Virol 70, 1605-1608

127A.D. Barrett and E.A. Gould (1986) Antibody-mediated early death in vivo after infection with yellow fever virus. J Gen Virol 67, 2539-2542

128J.J. Schlesinger and M.W. Brandriss (1981) Antibody-mediated infection of macrophages and macrophage-like cell lines with 17D-yellow fever virus. J Med Virol 8, 103-117

130S.B. Halstead and E.J. O'Rourke (1977) Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J Exp Med 146, 201-217

131A.P. Goncalvez (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104, 9422-9427

132S.B. Halstead (1979) In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 140, 527-533

133E. Mehlhop (2007) Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2, 417-426

134A.K. Broom (2000) Immunisation with gamma globulin to murray valley encephalitis virus and with an inactivated Japanese encephalitis virus vaccine as prophylaxis against australian encephalitis: evaluation in a mouse model. J Med Virol 61, 259-265

135S.W. Gollins and J.S. Porterfield (1984) Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate. J Gen Virol 65, 1261-1272

136T. Chareonsirisuthigul , S. Kalayanarooj and S. Ubol (2007) Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol 88, 365-375

137A. Suhrbier and M. La Linn (2003) Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends Immunol 24, 165-168

138D. Hober (2001) Antibody-dependent enhancement of coxsackievirus B4 infectivity of human peripheral blood mononuclear cells results in increased interferon-alpha synthesis. J Infect Dis 184, 1098-1108

139B.A. Lidbury and S. Mahalingam (2000) Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J Virol 74, 8376-8381

140S. Mahalingam and B.A. Lidbury (2003) Antibody-dependent enhancement of infection: bacteria do it too. Trends Immunol 24, 465-467

141A. Hamdan (2002) Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis 4, 160-162

142Z. Shimoni (2001) Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg Infect Dis 7, 759

S.S. Whitehead (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5, 518-528

K. Stiasny and F.X. Heinz (2006) Flavivirus membrane fusion. J Gen Virol 87, 2755-2766

J.S. Mackenzie , D.J. Gubler and L.R. Petersen (2004) Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10, S98-109

A.J. Della-Porta and E.G. Westaway (1978) A multi-hit model for the neutralization of animal viruses. J Gen Virol 38, 1-19

P.J. Klasse and Q.J. Sattentau (2002) Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol 83, 2091-2108

T.J. Smith (2003) Structural studies on antibody-virus complexes. Adv Protein Chem 64, 409-453

L. Hangartner , R.M. Zinkernagel and H. Hengartner (2006) Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6, 231-243

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *